secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001213900-24-046419
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties
--------------------------------------------------------------------------------

- ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.
- Upfront license fee of $12.5M (cash or OncoX shares) due in 30 days; additional $1.25M milestone after OncoX's next fundraising (no guarantee).
- ABVC entitled to 5% royalties on net sales, capped at $12.5M, after product launch (uncertain).
- BLEX 404 is a β-glucan extract from Maitake mushroom; FDA has approved four INDs for ABVC's oncology pipeline including ABV-1702 for MDS.
- No guarantee any fees or royalties will be received; partnership is early-stage and contingent on OncoX's fundraising and commercial success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/0001213900-24-046419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024046419/ea0206790-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-046419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer